MBX Biosciences, Inc. (NASDAQ:MBX – Get Free Report) was the target of a large drop in short interest in the month of January. Get MBX Biosciences alerts:Read Our Latest Report on MBX BiosciencesInstitutional Inflows and OutflowsMBX Biosciences Stock PerformanceSeveral large investors have recently bought and sold shares of the business. MBX Biosciences has a 12 month low of $4.81 and a 12 month high of $44.89. MBX Biosciences Company Profile(Get Free Report)We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. See AlsoReceive News & Ratings for MBX Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MBX Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.